IBI310&Sintilimab

Phase 3Monoclonal antibody

Innovent Biologics (Suzhou) Co. Ltd.

IBI310&Sintilimab is one of 27 small molecule programs targeting Neoadjuvant Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoadjuvant TreatmentRecruiting

Neoadjuvant TreatmentPhase 3

Recruiting

Competition

Competitive Landscape

27 competitors in Neoadjuvant Treatment

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

3 2

Abraxane

Bristol-Myers Squibb

Phase 3

2 3

Paraplatin

AAvyxa

Phase 3

7 4

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

5 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

4 6

Taxotere

AAvyxa

Phase 3

4 7

Adrucil

EElorac, Inc.

Phase 3

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

1 9

Eloxatin

Teva

Phase 2

6 10

Perjeta

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT06620822

Q3 2028

Phase 3Recruiting

Neoadjuvant Treatment

NCT05890742

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06620822·296 enrolled

Neoadjuvant Treatment1 trial

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT05890742·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IBI310&Sintilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IBI310&Sintilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IBI310&Sintilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovent Biologics (Suzhou) Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Innovent Biologics (Suzhou) Co. Ltd.

IBI310&Sintilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Neoadjuvant Treatment1 trial

References

Drug Info

Quick Facts

Related News